• | If you are a record holder (i.e., a stock certificate or uncertificated stock in book-entry form has been issued to you), you must complete and sign the enclosed Letter of Transmittal, in accordance with the instructions provided therein, and send it with your stock certificate (if applicable) and any other documents required in the Letter of Transmittal to Broadridge Corporate Issuer Solutions, LLC, the depositary for the Offer (the “Depositary”), or follow the procedures for book-entry transfer set forth in Section 3 of this Offer to Purchase. These materials must reach the Depositary prior to the expiration of the Offer. Detailed instructions are contained in the Letter of Transmittal and in “The Offer-Section 3-Procedures for Tendering Shares” of this Offer to Purchase. |
• | If you hold your Shares through a broker, dealer, commercial bank, trust company or other nominee, you must contact your broker, dealer, commercial bank, trust company or other nominee and give instructions that your Shares be tendered. |
Securities Sought | All of the outstanding shares of voting common stock, par value of $0.0001 per share (the “Voting Common Stock”) and non-voting common stock, par value of $0.0001 per share (the “Non-Voting Common Stock”) of Longboard (the “Shares”). | ||
Price Offered Per Share | $60.00, in cash, without interest, subject to any applicable withholding of taxes. | ||
Scheduled Expiration of Offer | One minute following 11:59 p.m., Eastern Time, on November 27, 2024, unless the Offer is extended or earlier terminated as permitted by the Merger Agreement. | ||
Purchaser | Langkawi Corporation, a Delaware corporation and a wholly owned subsidiary of Parent. | ||
• | the Offer is being made for all outstanding Shares solely for cash; |
• | as described above, we, through Parent and its controlled affiliates, will have sufficient funds available to acquire all Shares validly tendered, and not withdrawn, in the Offer and to provide funding for the Merger, which is expected to occur as promptly as reasonably practicable, on the same day as the Offer Acceptance Time (as defined below), subject to the satisfaction or waiver of the other conditions set forth in the Merger Agreement; |
• | consummation of the Offer is not subject to, or contingent upon, any financing condition; and |
• | if we consummate the Offer, we expect to acquire any remaining Shares for the same cash per Share price in the Merger. |
• | there have been validly tendered and not validly withdrawn shares of Voting Common Stock that, considered together with all other shares of Voting Common Stock (if any) beneficially owned by Parent or any of its wholly owned subsidiaries (but excluding shares of Voting Common Stock tendered pursuant to guaranteed delivery procedures that have not yet been received, as defined by Section 251(h)(6) of the DGCL), represent one share of Voting Common Stock more than 50% of the sum of (i) the total number of shares of Voting Common Stock outstanding at the time of the expiration of the Offer, plus (ii) the total number of shares of Voting Common Stock that Longboard is required to issue upon conversion, settlement, exchange or exercise of all Non-Voting Common Stock, options, warrants, rights or other securities for which the holder has, by the time of the expiration of the Offer, elected to convert, settle, exchange or exercise or for which the conversion, settlement, exchange or exercise date has already occurred by the time of the expiration of the Offer (but without duplication) (the “Minimum Condition”); |
• | (i) the representations and warranties of Longboard set forth in Section 3.1 (Due Organization and Good Standing), Section 3.2 (No Subsidiaries), Section 3.3 (Certificate of Incorporation and Bylaws), 3.4 (Authority; Binding Nature of Agreement), Section 3.5(b), (e) and (f) (Capitalization, Etc.), Section 3.7(a) (Non-Contravention; Consents) and Section 3.26 (Brokers and Other Advisors) shall be true and correct (without giving effect to any limitation as to “materiality” or “Material Adverse Effect” set forth therein) in all material respects at and as of the date of the Merger Agreement and at and as of the Offer Acceptance Time as if made on and as of such time (except to the extent any such representation or warranty is expressly made as of an earlier date or time, in which case as of such earlier date or time); (ii) the representations and warranties of Longboard set forth in Section 3.5(a), (c) and (d) (Capitalization, Etc.) shall be true and correct except for any de minimis inaccuracies at and as of the date of the Merger Agreement and at and as of the Offer Acceptance Time as if made on and as of such time (except to the extent any such representation or warranty is expressly made as of an earlier date or time, in which case as of such earlier date or time); (iii) the representations and warranties of Longboard set forth in Section 3.9(b) (No Material Adverse Effect) shall be true and accurate in all respects at and as of the date of the Merger Agreement and at and as of the Offer Acceptance Time as if made on and as of the Offer Acceptance Time (except to the extent any such representation or warranty expressly relates to an earlier date or period, in which case as of such date or period); and (iv) the representations and warranties of Longboard set forth in Section 3 (other than those referred to in clauses (i), (ii) and (iii) of this paragraph) shall be true and accurate (without giving effect to any limitation as to “materiality” or “Material Adverse Effect” set forth therein) at and as of the date of the Merger Agreement and at and as of the Offer Acceptance Time as if made on and as of the Offer Acceptance Time (except to the extent any such representation or warranty expressly relates to an earlier date or period, in which case as of such date or period), except where the failure of such representations and warranties to be so true and accurate has not had and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect (the “Representations Condition”); |
• | Longboard having complied with or performed in all material respects all of Longboard’s covenants and agreements it is required to comply with or perform at or prior to the Offer Acceptance Time (the “Obligations Condition”); |
• | Parent and Purchaser having received a certificate of Longboard, validly executed for and on behalf of Longboard and in its name by a duly authorized executive officer or chief financial officer thereof, certifying that the Representations Condition, the Obligations Condition and the MAE Condition (defined below) have been duly satisfied; |
• | (i) any waiting period (and any extension thereof) applicable to the Offer under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) shall have expired or terminated, and any agreement with any governmental body not to consummate the Offer mutually agreed to by the parties shall have |
• | there shall be no pending lawsuit by any governmental body explicitly seeking to impose a Remedy Action (defined in “The Offer-Section 13-The Transaction Documents-Regulatory Undertakings”) on any of the Parent, Longboard or any of their respective affiliates that is not a Required Remedy Action (defined in “The Offer-Section 13-The Transaction Documents-Regulatory Undertakings”) (the “Remedy Condition”); |
• | since the date of the Merger Agreement, there shall not have occurred any Material Adverse Effect that is continuing (the “MAE Condition”); and |
• | the Merger Agreement shall not have been terminated in accordance with its terms. |
• | determined that the entry into the Merger Agreement and the consummation of all of the transactions contemplated by the Merger Agreement, including the Offer and the Merger (the “Transactions”), are fair and advisable, and in the best interest of, Longboard and its stockholders; |
• | determined that the Merger shall be governed and effected in accordance with Section 251(h) of the DGCL; |
• | authorized and approved the execution, delivery and performance by Longboard of the Merger Agreement and the consummation of the Transactions, including the Offer and the Merger; and |
• | resolved to recommend that the holders of Shares accept the Offer and tender their Shares to Purchaser pursuant to the Offer. |
• | If you are a record holder (i.e., a stock certificate or uncertificated stock in book-entry form has been issued to you), you must complete and sign the enclosed Letter of Transmittal in accordance with the instructions provided therein, and send it with your stock certificates (if applicable) and any other documents required in the Letter of Transmittal to the Depositary or follow the procedures for book-entry transfer set forth in Section 3 of this Offer to Purchase. These materials must reach the Depositary prior to the Expiration Time. Detailed instructions are contained in the Letter of Transmittal and in “The Offer-Section 3-Procedures for Tendering Shares.” |
• | If you hold your Shares through a broker, dealer, commercial bank, trust company or other nominee, you must contact your broker, dealer, commercial bank, trust company or other nominee and give instructions that your Shares be tendered. |
Terms of the Offer |
Acceptance for Payment and Payment for Shares |
Procedures for Tendering Shares |
Withdrawal Rights |
Material U.S. Federal Income Tax Consequences |
• | a bank, financial institution, or insurance company; |
• | a mutual fund; |
• | entities or arrangements treated as partnerships or other pass-through entities for U.S. federal income tax purposes or investors therein; |
• | a tax-exempt organization (including a private foundation); |
• | a governmental or international organization; |
• | a dealer or broker in securities or currencies; |
• | a U.S. Holder whose functional currency is not the U.S. dollar; |
• | a former citizen or former long-term resident of the United States; |
• | a regulated investment company or real estate investment trust; |
• | “controlled foreign corporations,” “passive foreign investment companies,” or corporations that accumulate earnings to avoid U.S. federal income tax; |
• | a stockholder that holds its Shares through individual retirement or other tax-deferred accounts; |
• | a trader in securities who elects to apply a mark-to-market method of accounting; |
• | a stockholder that holds Shares as part of a hedge, appreciated financial position, straddle, or conversion or integrated transaction; |
• | a stockholder that acquired Shares through the exercise of compensatory options or stock purchase plans or otherwise as compensation for services or in connection with the performance of services; |
• | an entity covered by the anti-inversion rules under the Code; |
• | a person holding Shares as “qualified small business stock” within the meaning of Section 1202 of the Code or “Section 1244 stock” for purposes of Section 1244 of the Code; |
• | a person who actually or constructively owns more than 5% of the outstanding Shares; and |
• | a person who holds both Shares and common stock of Parent. |
• | an individual who is a citizen or resident of the United States; |
• | a corporation, or other entity or arrangement treated as a corporation for U.S. federal income tax purposes, created or organized in or under the laws of the United States or any state therein or the District of Columbia; |
• | an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or |
• | a trust (a) that is subject to the primary supervision of a court within the United States and all the substantial decisions of which are controlled by one or more U.S. persons or (b) that has a valid election in effect under applicable U.S. Treasury regulations to be treated as a U.S. person. |
• | the gain, if any, on the sale of Shares pursuant to the Offer is effectively connected with the conduct by the Non-U.S. Holder of a trade or business in the United States (and, if required by an applicable income tax treaty, is attributable to the Non-U.S. Holder’s permanent establishment in the United States); |
• | the Non-U.S. Holder is an individual who was present in the United States for 183 days or more in the taxable year of the sale of Shares pursuant to the Offer and certain other conditions are met; or |
• | the Non-U.S. Holder’s Shares constitute “United States real property interests” (“USRPIs”) by reason of Longboard being treated as a “United States real property holding corporation” (“USRPHC”) for U.S. federal income tax purposes at any time within the shorter of the five-year period preceding the sale of Shares pursuant to the Offer and the Non-U.S. Holder’s holding period in the Non-U.S. Holder’s Shares. |
Price Range of Shares; Dividends |
High | Low | |||||
2022 | ||||||
Fourth Quarter | $5.88 | $2.70 | ||||
2023 | ||||||
First Quarter | $6.23 | $3.39 | ||||
Second Quarter | $10.29 | $3.90 | ||||
Third Quarter | $7.71 | $5.36 | ||||
Fourth Quarter | $6.50 | $3.60 | ||||
2024 | ||||||
First Quarter | $28.15 | $16.20 | ||||
Second Quarter | $28.13 | $15.64 | ||||
Third Quarter | $40.48 | $24.76 | ||||
Fourth Quarter (through October 29) | $59.79 | $32.56 | ||||
Possible Effects of the Offer on the Market for the Shares; Stock Exchange Listing; Registration under the Exchange Act; Margin Regulations |
Certain Information Concerning Longboard |
Certain Information Concerning Parent, Payor and Purchaser |
Source and Amount of Funds |
• | the Offer is not subject to any financing condition; |
• | if Purchaser consummates the Offer, it will acquire all remaining Shares for the same consideration in the Merger; |
• | the Offer is being made for all outstanding Shares solely for cash; and |
• | Parent and/or one or more of its affiliates has, and will arrange for Purchaser to have, sufficient funds available to pay the Merger Consideration in respect of all Shares validly tendered in the Offer, and not properly withdrawn, prior to the Expiration Time, to acquire the remaining outstanding Shares in the Merger. |
Background of the Offer; Contacts with Longboard |
Purpose of the Offer; Plans for Longboard; Stockholder Approval; Appraisal Rights |
• | within the later of the consummation of the Offer and 20 days after the mailing of the Schedule 14D-9, deliver to Longboard a written demand for appraisal of Shares held, which demand must reasonably inform Longboard of the identity of the stockholder and that the stockholder is demanding appraisal; |
• | not tender their Shares in the Offer; |
• | continuously hold of record or beneficially own the Shares from the date on which the written demand for appraisal is made through the Merger Effective Time (and in the case of Shares beneficially owned, such beneficial owner must reasonably identify the record holder of such Shares by documentary evidence of such beneficial ownership and a statement that such documentary evidence is a true and correct copy of what it purports to be, and provide an address at which such beneficial owner consents to receive notices); and |
• | strictly follow the statutory procedures for perfecting appraisal rights under Section 262 of the DGCL. |
The Transaction Documents |
• | establish a record date for, declare, set aside or pay any dividend or make any other distribution in respect of any shares of its capital stock (including the Shares); |
• | repurchase, redeem or otherwise reacquire any of its shares of capital stock (including any Shares), or any rights, warrants or options to acquire any shares of its capital stock, subject to customary exceptions; |
• | split, combine, subdivide or reclassify any shares of its capital stock (including the Shares) or other equity interests; |
• | sell, issue, grant, deliver, pledge, transfer, encumber or authorize the issuance, sale, delivery, pledge, transfer, encumbrance or grant by Longboard of (A) any capital stock, equity interest or other security of Longboard, (B) any option, call, warrant, restricted securities or right to acquire any capital stock, equity interest or other security of Longboard or (C) any instrument convertible into or exchangeable for any capital stock, equity interest or other security of Longboard (except that Longboard may (1) issue Shares as required to be issued upon the settlement of Longboard RSUs outstanding on the date of the Merger Agreement, upon the exercise of Longboard Options, or the vesting of Longboard Awards outstanding as of the date of the Merger Agreement in accordance with the terms of any such Longboard Award (in effect as of the date of the Merger Agreement), (2) sell shares upon exercise of Longboard Options if necessary to effectuate an optionee direction upon exercise or sales to satisfy the exercise price or tax obligations with respect to Longboard Awards outstanding as of the date of the Merger Agreement in accordance with the terms of any such Longboard Award (in effect as of the date of the Merger Agreement) and (3) authorize purchases of Shares under a Rule 10b5-1 plan established by Longboard in accordance with the terms of any such Rule 10b5-1 plan (in effect as of the date of the Merger Agreement)); |
• | except as required by the terms of any compensation or employee benefit plan, policy, program, arrangement, practice or agreement of Longboard (an “Employee Plan”) or as required by applicable law, (A) increase the compensation payable or to become payable or the benefits provided to any Longboard employee or other individual service provider, (B) establish, adopt, terminate or amend any Employee Plan (or any plan, policy, program, arrangement, practice or agreement that would be an Employee Plan if it were in existence on the date of the Merger Agreement), (C) grant any equity or equity-based awards to any Longboard employee or other individual service provider, or (D) amend or waive any of its rights under, or accelerate the vesting or timing of payment, or fund or in any other way secure the payment, in respect of any award or benefit provided under any Employee Plan (or any plan, policy, program, arrangement, practice or agreement that would be an Employee Plan if it were in existence on the date of the Merger Agreement), subject to customary exceptions; |
• | (A) grant any change-of-control or retention payments or benefits (or provide for any increase thereof) to, or enter into any change-of-control or retention agreement with, any Longboard employee or other individual service provider, (B) grant any severance payments or benefits (or provide for any increase thereof) to, or enter into any employment or severance agreement with, any executive officer or director, (C) grant any severance or termination payments or benefits (or provide for any increase thereof) to, or enter into any employment or severance agreement with any non executive officer employee with an annual base salary greater than $300,000 or any consulting agreement with an individual independent contractor with an annual base compensation greater than $300,000 or (D) hire any employee that would be a direct report to the Chief Executive Officer of Longboard or any employee with an annual base salary in excess of $300,000; |
• | amend or permit the adoption of any amendment to the certificate of incorporation, the bylaws or other charter or organizational documents of Longboard; |
• | form a subsidiary; |
• | directly or indirectly acquire or agree to acquire (including by merger, consolidation or acquisition of stock or assets) any equity interest in, or a material portion of the assets or business of, any other entity; |
• | make any loans, advances or capital contributions to, or investments in, any other person, except for (A) advances for employee expenses in the ordinary course of business, or (B) the extension of trade credit in the ordinary course of business; |
• | enter into any corporate joint venture, development, partnership, limited liability corporation or similar arrangement, in each case, for the sharing of profits and losses; |
• | make or authorize any capital expenditure except (A) in the ordinary course of business and not to exceed $50,000 individually or $250,000 in the aggregate, or (B) in connection with the repair or replacement of facilities, properties or assets destroyed or damaged due to casualty or accident (to the extent not covered by insurance); |
• | acquire, sell, lease, license, sublicense, pledge, transfer or otherwise dispose of, divest or spin-off, abandon, waive, covenant not to assert, relinquish or permit to lapse, transfer, or assign any material right or other |
• | negotiate or enter into any license and collaboration, partnership or distribution contract or other similar transaction with respect to any assets pertaining to any products (including pipeline products) or research or development programs of Longboard, subject to customary exceptions; |
• | acquire, sell, lease, license, sublicense, pledge, transfer or otherwise dispose of, divest or spin-off, abandon, waive, covenant not to assert, relinquish or permit to lapse (other than any patent expiring at the end of its statutory term and not capable of being extended), transfer, or assign any material intellectual property rights, including material intellectual property rights pertaining to earlier pipeline projects or programs related to bexicaserin, except pursuant to (A) non-exclusive licenses or sublicenses made in the ordinary course of business consistent with past practice (including entering into clinical trial agreements and material transfer agreements in the ordinary course of business and consistent with past practice) that are not related to bexicaserin, (B) non-exclusive licenses or sublicenses related to bexicaserin made in the ordinary course of business consistent with past practice that are incidental to a manufacturing, services or clinical trial agreement and granted to a person solely with limited rights to perform services for Longboard or (C) decisions made regarding the prosecution and maintenance of intellectual property rights, including the Longboard owned intellectual property and the Longboard licensed intellectual property, in the ordinary course of business consistent with past practice except for decisions to abandon or permit to lapse -patents or patent applications related to bexicaserin or any claim in any patent in each case within the Longboard owned intellectual property or Longboard licensed intellectual property where such abandonment or lapse of such claim would materially degrade the scope of protection related to bexicaserin; |
• | incur any indebtedness after the date of the Merger Agreement, except for (A) indebtedness reasonably necessary to finance capital expenditures, (B) indebtedness incurred to refinance or replace existing indebtedness (including any increased amounts of indebtedness to the extent necessary to finance any fees, costs and expenses incurred in connection with such refinancing or replacement), (C) letters of credit, bank guarantees, security or performance bonds or similar credit support instruments, overdraft facilities or cash management programs, in each case issued, made or entered into in the ordinary course of business and (D) indebtedness incurred under any existing credit facilities or similar arrangements as in effect on the date hereof, in each case of clauses (A) through (D), in any amount less than $500,000 per incurrence or $1,000,000 in the aggregate; |
• | lend money or make capital contributions or advances to or make investments in, any person, or incur or guarantee any indebtedness (except for advances to employees and consultants for travel and other business related expenses in the ordinary course of business consistent with past practice and in compliance with Longboard’s policies related thereto); |
• | (A) negotiate or enter into any contract that would constitute a material contract if it had been in effect on the date of the Merger Agreement or (B) amend or modify in any material respect, or waive or release any material rights under or voluntarily terminate, any material contract; |
• | except as required by GAAP, in the ordinary course of business, or as would not have a material effect on Longboard’s tax liability, (A) make, revoke or change any material tax election; (B) settle or compromise any material tax claim or assessment or affirmatively surrender a right to any material tax refund; (C) change any accounting period used for tax purposes; (D) file an amended material tax return; (E) enter into a closing agreement with any governmental body regarding any material tax liability or assessment; (F) consent to any extension or waiver of any limitation period with respect to any material tax claim or assessment (other than in connection with a customary extension of time automatically granted to file a tax return of no longer than seven (7) months); or (G) fail to pay any material tax as it becomes due and payable, except to the extent such tax is contested in good faith; |
• | commence any legal proceeding, except with respect to: (A) routine matters in the ordinary course of business consistent with past practice; or (B) in connection with a breach of the Merger Agreement; |
• | settle, release, waive or compromise any legal proceeding or other claim (or threatened legal proceeding or other claim), other than (A) any legal proceeding relating to a breach of the Merger Agreement or any other agreements contemplated hereby, (B) a settlement that results solely in a monetary obligation involving only the payment of monies (without admission of wrongdoing) by Longboard (net of recoveries under insurance policies or indemnity obligations) of not more than $500,000 in the aggregate and provides for a complete release of the claims in dispute giving rise to such settlement, release, waiver or compromise or (C) a settlement that results in no monetary obligation of Longboard or Longboard’s receipt of payment; provided, that in each case, such settlement, release, waiver or compromise (x) does not relate to any intellectual property rights, (y) is not entered into with any governmental body, (z) does not involve any material injunctive or equitable relief, or impose restrictions, on the business activities of Longboard; and provided further that the settlement, release, waiver or compromise of any legal proceeding or claim brought by the stockholders of Longboard against Longboard or its directors relating to the transactions contemplated by the Merger Agreement or a breach of the Merger Agreement or any other agreements contemplated by the Merger Agreement; |
• | enter into any collective bargaining agreement or other agreement with any labor organization (except to the extent required by applicable law); |
• | adopt or implement any stockholder rights plan or similar arrangement; |
• | adopt a plan or agreement of complete or partial liquidation or dissolution, consolidation, restructuring, recapitalization or other reorganization of Longboard; |
• | relinquish, abandon or permit to lapse, or fail to take any action necessary to maintain, enforce and protect, any of its material intellectual property rights; |
• | enter into any new line of business outside pharmaceuticals; |
• | fail to maintain in full force and effect insurance policies covering Longboard and its material properties, business, assets and operations in a form and amount consistent with past practice in all material respects; or |
• | authorize, or agree or commit to take, any of the foregoing actions. |
• | terminate access by any third party (other than Parent, its affiliates and their respective representatives) to any physical or electronic data room or similar information sharing platform relating to any potential Acquisition Proposal or any proposal or offer that could reasonably be expected to lead to an Acquisition Proposal and |
• | request the prompt return or destruction of any confidential information previously furnished or made available to such persons and their representatives through such platform or in connection with a possible Acquisition Proposal. |
• | solicit, initiate or knowingly facilitate or knowingly encourage (including by way of furnishing non public information) any Acquisition Proposal or any inquiries regarding, or the making of any proposal or offer that constitutes, or could reasonably be expected to lead to, an Acquisition Proposal, |
• | engage in or otherwise participate in any discussions or negotiations regarding, or furnish to any other person any information in connection with, or for the purpose of, soliciting, initiating or knowingly facilitating or encouraging, an Acquisition Proposal or any proposal or offer that could reasonably be expected to lead to an Acquisition Proposal; |
• | adopt, approve or enter into any letter of intent, acquisition agreement, agreement in principle or similar contract with respect to an Acquisition Proposal or any proposal or offer that could reasonably be expected to lead to an Acquisition Proposal; or |
• | waive or release any person from, fail to use reasonable best efforts to enforce any standstill, non-use, non-contact or similar agreement or any standstill, non-use, non-contact or similar provisions of any contract with respect to any Acquisition Proposal or any proposal or offer that could reasonably be expected to lead to an Acquisition Proposal. |
• | acquisition, purchase or license, directly or indirectly, of assets of Longboard equal to 15% or more of Longboard’s assets or to which 15% or more of the revenues or earnings of Longboard are attributable, determined in each case on a consolidated basis, |
• | issuance by Longboard, purchase or acquisition of 15% or more of any class of any capital stock, ordinary shares, other equity interests or other equity securities of Longboard, including any outstanding Voting Common Stock or Non-Voting Common Stock, |
• | recapitalization, tender offer or exchange offer that if consummated would result in any person or group beneficially owning 15% or more of any class of any capital stock, ordinary shares, other equity interests or other equity securities of Longboard, including any outstanding Voting Common Stock or Non-Voting Common Stock, or |
• | merger, consolidation, amalgamation, share exchange, business combination, recapitalization, liquidation, dissolution or similar transaction involving Longboard that if consummated would result in any person or group beneficially owning 15% or more of any class of any capital stock, ordinary shares, other equity interests or other equity securities of Longboard, including any outstanding Voting Common Stock or Non-Voting Common Stock, in each case, other than the Transactions. |
• | Longboard and its representatives may request that any oral Acquisition Proposal be provided in written form and inform such person or group of persons of the terms of Longboard’s non-solicitation obligations, |
• | if the Longboard Board determines in good faith, after consultation with its financial advisors and outside legal counsel, that such Acquisition Proposal constitutes or would reasonably be expected to lead to a Superior Proposal and the failure to take the actions described above would be inconsistent with the fiduciary duties of the Longboard Board under applicable law (and Longboard provides Parent with written notice of this determination prior to the first time that Longboard takes any action with respect to such Acquisition Proposal), then Longboard and its representatives may (x) enter into a customary confidentiality agreement that satisfies certain criteria specified in the Merger Agreement (an “Acceptable Confidentiality Agreement”), and furnish pursuant to such Acceptable Confidentiality Agreement information (including non public information) with respect to Longboard to the person or group of persons who have made such Acquisition Proposal and their respective representatives (however, Longboard must concurrently provide to Parent any information concerning Longboard that is provided to any person given such access which was not previously provided to Parent or its representatives) and (y) engage in or otherwise participate in discussions or negotiations with the person or group of persons making such Acquisition Proposal and their respective representatives with respect to such Acquisition Proposal. |
• | promptly (and in any event within 36 hours) notify Parent if any inquiries, proposals, indications of interest or offers that are Acquisition Proposals or could reasonably be expected to lead to an Acquisition Proposal, including any requests to engage in communications, discussions or negotiations with respect to any Acquisition Proposal, are received, whether orally or in writing, by Longboard or any of its representatives together with the identity of the person or group of persons making such inquiries, proposals, indications of interest or offers, |
• | promptly (and in any event within 36 hours) provide to Parent a copy of any written Acquisition Proposal or written materials comprising such inquiry, proposal or offer received by Longboard or any of its representatives and a summary of the material terms and conditions of any oral Acquisition Proposal or any such inquiry, proposal, indication of interest or offer, |
• | keep Parent reasonably informed of any material developments regarding any Acquisition Proposal on a prompt basis and |
• | upon the reasonable written request of Parent, reasonably inform Parent of the status of such Acquisition Proposal. |
• | withdraw (or modify, change or qualify in a manner adverse to Parent or Purchaser), or publicly propose to withdraw (or modify, change or qualify in a manner adverse to Parent or Purchaser), the Longboard Board Recommendation; |
• | adopt, approve, recommend or declare advisable, or publicly propose to adopt, approve, recommend or declare advisable, any Acquisition Proposal; |
• | if a tender offer or exchange offer for the Shares that constitutes an Acquisition Proposal is commenced (within the meaning of 14d-2 under the Exchange Act), fail to recommend against acceptance of such tender offer or exchange offer within ten (10) business days; or |
• | if any Acquisition Proposal has been made public, fail to reaffirm the Longboard Board Recommendation upon request of Parent within the earlier of three (3) business days prior to the then-scheduled Expiration Time or ten (10) business days after Parent requests such reaffirmation with respect to such Acquisition Proposal. |
• | the Longboard Board determines in good faith (after consultation with its financial advisors and outside legal counsel) that the applicable Acquisition Proposal is a Superior Proposal; |
• | such Acquisition Proposal did not result from or arise out of a material breach of the obligations of Longboard described above under “No Solicitation”; |
• | the Longboard Board determines in good faith (after consultation with its outside legal counsel) that the failure to take such action would be inconsistent with the fiduciary duties of the Longboard Board under applicable laws; |
• | Longboard has given Parent prior written notice of its intention to consider making an Adverse Change Recommendation or terminate the Merger Agreement to accept such Acquisition Proposal, together with any proposed definitive or other agreements (including schedules and exhibits thereto), with respect to such Acquisition Proposal, at least four business days prior to making any such Adverse Change Recommendation and, if applicable, effecting such termination (a “Determination Notice”); |
• | Longboard has provided to Parent the information and materials (including a copy of any proposed agreements and related financing agreements) and a summary of the material terms and conditions of such Acquisition Proposal; |
• | Longboard has given Parent four business days after delivery of the Determination Notice to propose revisions to the terms of the Merger Agreement or make other proposals so that such Acquisition Proposal would cease to constitute a Superior Proposal and has negotiated and caused its representatives to negotiate in good faith with Parent and its representatives (to the extent Parent desires and has requested to negotiate) with respect to such proposed revisions or other proposal, if any; and |
• | the Longboard Board, after consultation with Longboard’s financial advisers and outside legal counsel and taking into account and giving effect to any amendments to the Merger Agreement and the Transactions proposed by Parent and any other proposals made by Parent, the Longboard Board has determined, in good faith, that such Acquisition Proposal continues to constitute a Superior Proposal and that the failure to make the Adverse Change Recommendation or terminate the Merger Agreement to accept such Superior Proposal would be inconsistent with the fiduciary duties of the Longboard Board under applicable laws. |
• | the Longboard Board determines in good faith (after consultation with its outside legal counsel) that the failure to do so would be inconsistent with the fiduciary duties of the Longboard Board under applicable laws; |
• | Longboard has given Parent a Determination Notice at least four business days prior to making any such Adverse Change Recommendation (which notice describes the Change in Circumstances in reasonable detail); |
• | Longboard has given Parent four business days after delivery of the Determination Notice to propose revisions to the terms of the Merger Agreement or make other proposals so that such Change in Circumstance would no longer necessitate an Adverse Change Recommendation, and, to the extent requested by Parent, has negotiated, and caused its representatives to negotiate in good faith with Parent with respect to such proposed revisions or other proposal, if any; and |
• | the Longboard Board, after consultation with Longboard’s financial advisers and outside legal counsel, taking into account, and giving effect to, any amendments to the Merger Agreement and the Transactions proposed by Parent, and any other proposals made by Parent, has determined, in good faith, that the failure to make the Adverse Change Recommendation in response to such Change in Circumstance would be inconsistent with the fiduciary duties of the Longboard Board under applicable law. |
• | There will not have been issued by any governmental body of competent jurisdiction and remain in effect any temporary restraining order, preliminary or permanent injunction or other order preventing the consummation of the Merger, nor will any applicable law or order have been entered, enforced, promulgated, enacted or issued after the date of the Merger Agreement by any Governmental Body and remain in effect, in each case, which prohibits, or makes illegal the consummation of the Merger (the “Restraints Condition”); and |
• | Purchaser (or Parent on Purchaser’s behalf) will have accepted for payment all of the Shares validly tendered pursuant to the Offer and not validly withdrawn. |
• | by mutual written consent of Parent and Longboard at any time prior to the Offer Acceptance Time; |
• | by either Parent or Longboard if a court of competent jurisdiction or other governmental body has issued an order, injunction, decree or ruling, or has taken any other action, having the effect of permanently restraining, enjoining or otherwise prohibiting the acceptance for payment of Shares pursuant to the Offer or the Merger or making consummation of the Offer or the Merger illegal, which order, injunction, decree, ruling or other action is final and nonappealable, or a governmental body will have entered, enforced, enacted, or issued a law after the date hereof having the effect of permanently restraining, enjoining or otherwise prohibiting the acceptance for payment of Shares pursuant to the Offer or the Merger or making consummation of the Offer or the Merger illegal. The right to terminate the Merger Agreement pursuant to this provision will not be available to a party if, in the case of Longboard, its, and in the case of Parent, its, Payor’s or Purchaser’s, material breach of any provision of the Merger Agreement will have been the cause of, or has resulted in, the issuance of such final and nonappealable order, injunction, decree, ruling or other action “Legal Restraint Termination”; |
• | by either Parent or Longboard, if the Offer Acceptance Time will not have occurred on or prior to 11:59 p.m. Eastern Time on the Termination Date; provided, however, that in the event that on the original Termination Date, any of the Regulatory Conditions (in connection with or in respect of any matter involving Antitrust Law), or Remedy Condition have not been satisfied but all of the other closing conditions (other than the Minimum Condition) have been satisfied or waived (or would have been capable of being satisfied or waived if the Offer Acceptance Time had occurred), then the Termination Date will be automatically extended without further action by the parties until 11:59 p.m. Eastern Time on October 14, 2025 (and in the case of such extension, any reference to the Termination Date in the Merger Agreement will be a reference to the Termination Date, as extended); provided, further that the right to terminate the Merger Agreement pursuant to this paragraph will not be available to any party if its (or in the case of Parent, Parent, Payor or Purchaser’s) material breach of any provision of the Merger Agreement will have been the cause of, or resulted in, the failure of the Offer Acceptance Time to occur by the Termination Date. We refer to any termination of the Merger Agreement pursuant to this provision as a “Termination Date Termination”; |
• | by Longboard, if Purchaser will have failed to commence (within the meaning of Rule 14d-2 under the Exchange Act) the Offer within the period specified in the Merger Agreement or if Purchaser will have failed to accept and pay for all Shares validly tendered (and not validly withdrawn) as of the expiration of the Offer (as may be extended) pursuant to the Merger Agreement after the satisfaction, or to the extent waivable by Purchaser, Payor or Parent, waiver by Purchaser, Payor or Parent, of each of the Offer Conditions; |
• | by Parent at any time prior to the Offer Acceptance Time, if Longboard has breached or failed to perform any of its covenants or other agreements contained in the Merger Agreement, or if any of the representations or warranties of Longboard in the Merger Agreement is inaccurate, which breach, failure to perform or inaccuracy would result in the Representations Condition or the Obligations Condition, as |
• | by Parent at any time prior to the Offer Acceptance Time, if (i) the Longboard Board will have failed to include the Longboard Board Recommendation in the Schedule 14D-9 when filed with the SEC or disseminated to Longboard stockholders, or will have made an Adverse Change Recommendation; (ii) in the case of a tender offer or exchange offer subject to Regulation 14D under the Exchange Act, other than the Offer, the Longboard Board fails to recommend, in a Solicitation/Recommendation Statement on Schedule 14D-9, rejection of such tender offer or exchange offer within the earlier of (A) the third (3rd) business prior to the then-applicable Expiration Time or (B) ten (10) business days of the commencement of such tender offer or exchange offer; (iii) an Acquisition Proposal is publicly disclosed (whether by Longboard or a third party) or otherwise publicly made known to Longboard stockholders and in each case is not publicly withdrawn or is otherwise received by Longboard (whether or not public), other than the Offer, the Longboard Board fails to publicly recommend rejection of such Acquisition Proposal within three (3) business days after being requested to do so in writing by Parent (or, with respect to such Acquisition Proposal that is a tender offer or exchange offer subject to Regulation 14D under the Exchange Act, within the earlier of (3) business days prior to the then-applicable Expiration Time or ten (10) business days of the date such Acquisition Proposal was made public); or (iv) the Longboard Board (or a duly authorized committee thereof) makes and has not withdrawn an Adverse Change Recommendation. We refer to any termination of the Merger Agreement pursuant to this provision as a “Change in Recommendation Termination”. |
• | by Longboard at any time prior to the Offer Acceptance Time, if Parent, Payor or Purchaser has breached or failed to perform any of its respective covenants or other agreements contained in the Merger Agreement, or if any of the representations or warranties of Longboard in the Merger Agreement is inaccurate, which breach, failure to perform or inaccuracy would or would reasonably be expected to prevent Parent or Purchaser from consummating the Transactions, except that if such breach, failure or inaccuracy is capable of being cured by the Termination Date, Longboard will not be entitled to terminate the Merger Agreement pursuant to this paragraph prior to the delivery by Longboard to Parent of written notice of such breach, delivered at least thirty days prior to such termination (or such shorter period of time as remains prior to the Termination Date, the shorter of such periods, the “Parent Breach Notice Period”), stating Longboard’s intention to terminate the Merger Agreement pursuant to this paragraph and the basis for such termination, it being understood that Longboard will not be entitled to terminate the Merger Agreement if such breach, failure or inaccuracy has been cured prior to the expiration of the Parent Breach Notice Period (to the extent capable of being cured); provided, however, that Longboard will not have the right to terminate the Merger Agreement pursuant to this paragraph if Longboard is then in material breach of any representation, warranty, covenant or agreement of the Merger Agreement. We refer to any termination of the Merger Agreement pursuant to this provision as a “Parent Breach Termination”; |
• | by Longboard at any time prior to the Offer Acceptance Time, after compliance with the non-solicitation obligations of Longboard, in order to accept a Superior Proposal and concurrently enter into an acquisition agreement providing for the consummation of such Superior Proposal; provided that Longboard will have paid the Termination Fee (as defined below) to Parent prior to or concurrently with, and as a condition to, such termination. We refer to any termination of the Merger Agreement pursuant to this provision as a “Specified Proposal Termination”; or |
• | by either Parent or Longboard at any time prior to the Offer Acceptance Time, if the Offer (as it may be required to be extended pursuant to the Merger Agreement, or has otherwise been extended in accordance with the Merger Agreement) will have expired in accordance with its terms without the Minimum Condition having been satisfied or the other Offer Conditions having been satisfied or waived by Parent, in each case without the acceptance for payment of any Shares validly tendered in the Offer; provided, that the right to terminate the Merger Agreement pursuant to this paragraph will not be available to any party whose material breach of any agreements or covenants under the Merger Agreement has caused or resulted in the non-satisfaction of the Minimum Condition or any of the other Offer condition. We refer to any termination of the Merger Agreement pursuant to this provision as a “Minimum Condition Termination.” |
• | the Merger Agreement is terminated by Longboard pursuant to a Specified Proposal Termination in which case Longboard must prior to or concurrently with, and as a condition to, such termination pay to Parent the Termination Fee; |
• | the Merger Agreement is terminated by Parent pursuant to a Change in Recommendation Termination in which case Longboard must prior to or concurrently with, and as a condition to, such termination pay to Parent the Termination Fee; or |
• | if (i) (A) the Merger Agreement is terminated pursuant to a Termination Date Termination, (B) the Merger Agreement is terminated pursuant to a Minimum Condition Termination or (C) if the Merger Agreement is terminated pursuant to a Longboard Breach Termination, (ii) (A) an Acquisition Proposal is publicly disclosed (whether by Longboard or a third party) or otherwise publicly made known to the Longboard Board or Longboard stockholders and in each case is not publicly withdrawn prior to the date of any such termination (but in the case of the preceding clause (i)(B), even if publicly withdrawn, such public withdrawal was at least three business days prior to the applicable Expiration Time) in any case of the preceding clause (i), or (B) solely in case of any of the preceding clauses (i)(A) or (i)(C), a non-public Acquisition Proposal has been made to the Longboard Board or any person has privately disclosed or communicated to the Longboard Board an intention to make an Acquisition Proposal which has not been withdrawn (publicly, if public) at the time of such termination, and (iii) within twelve months after the applicable termination, (A) the Longboard Board publicly recommends in writing that stockholders vote in favor of, or tender their shares into, any Acquisition Proposal or (B) Longboard will have entered into a definitive agreement with respect to or consummated any Acquisition Proposal, then Longboard will pay to Parent or its designee the Termination Fee in immediately available funds concurrently with the earliest to occur of such recommendation, such entry into such definitive agreement or such consummation of such Acquisition Proposal; however, Longboard will not be required to pay the Termination Fee on more than one occasion (with the references to “15%” in the definition of “Acquisition Proposal” being deemed to be references to “50%”). |
Dividends and Distributions |
Conditions to the Offer |
• | there have been validly tendered and not validly withdrawn shares of Voting Common Stock that, considered together with all other shares of Voting Common Stock (if any) beneficially owned by Parent or any of its wholly owned subsidiaries (but excluding shares of Voting Common Stock tendered pursuant to guaranteed delivery procedures that have not yet been received, as defined by Section 251(h)(6) of the DGCL), represent one share of Voting Common Stock more than 50% of the sum of (i) the total number of shares of Voting Common Stock outstanding at the time of the expiration of the Offer, plus (ii) the total number of shares of Voting Common Stock that Longboard is required to issue upon conversion, settlement, exchange or exercise of all Non-Voting Common Stock, options, warrants, rights or other securities for which the holder has, by the time of the expiration of the Offer, elected to convert, settle, exchange or exercise or for which the conversion, settlement, exchange or exercise date has already occurred by the time of the expiration of the Offer (but without duplication) (the “Minimum Condition”); |
• | (i) the representations and warranties of Longboard set forth in Section 3.1 (Due Organization and Good Standing), Section 3.2 (No Subsidiaries), Section 3.3 (Certificate of Incorporation and Bylaws), 3.4 (Authority; Binding Nature of Agreement), Section 3.5(b), (e) and (f) (Capitalization, Etc.), Section 3.7(a) (Non-Contravention; Consents) and Section 3.26 (Brokers and Other Advisors) shall be true and correct (without giving effect to any limitation as to “materiality” or “Material Adverse Effect” set forth therein) in all material respects at and as of the date of the Merger Agreement and at and as of the Offer Acceptance Time as if made on and as of such time (except to the extent any such representation or warranty is expressly made as of an earlier date or time, in which case as of such earlier date or time); (ii) the representations and warranties of Longboard set forth in Section 3.5(a), (c) and (d) (Capitalization, Etc.) shall be true and correct except for any de minimis inaccuracies at and as of the date of the Merger Agreement and at and as of the Offer Acceptance Time as if made on and as of such time (except to the extent any such representation or warranty is expressly made as of an earlier date or time, in which case as of such earlier date or time); (iii) the representations and warranties of Longboard set forth in Section 3.9(b) (No Material Adverse Effect) shall be true and accurate in all respects at and as of the date of the Merger Agreement and at and as of the Offer Acceptance Time as if made on and as of the Offer |
• | Longboard having complied with or performed in all material respects all of Longboard’s covenants and agreements it is required to comply with or perform at or prior to the Offer Acceptance Time (the “Obligations Condition”); |
• | Parent and Purchaser having received a certificate of Longboard, validly executed for and on behalf of Longboard and in its name by a duly authorized executive officer or chief financial officer thereof, certifying that the Representations Condition, the Obligations Condition and the MAE Condition (defined below) have been duly satisfied; |
• | (i) any waiting period (and any extension thereof) applicable to the Offer under the HSR Act shall have expired or terminated, and any agreement with any governmental body not to consummate the Offer mutually agreed to by the parties shall have expired or terminated, and (ii) no temporary restraining order, preliminary or permanent injunction or other order preventing the acquisition of or payment for Shares pursuant to the Offer or the consummation of the Offer or the Merger shall have been issued by any court of competent jurisdiction after the date hereof and remain in effect, nor shall any law have been entered, enforced, enacted, or issued after the date hereof by any governmental body and remain in effect, in each case, which prohibits, or makes illegal the acquisition of or payment for Shares pursuant to the Offer, or the consummation of the Merger (each of the conditions in clauses “(i)” and “(ii)” (in case of “(ii)”, as such condition directly relates to the HSR Act), the “Regulatory Condition”); |
• | there shall be no pending lawsuit by any governmental body explicitly seeking to impose a Remedy Action (defined in “The Offer-Section 13-The Transaction Documents-Regulatory Undertakings”) on any of the Parent, Longboard or any of their respective affiliates that is not a Required Remedy Action (defined in “The Offer-Section 13-The Transaction Documents-Regulatory Undertakings”) (the “Remedy Condition”); |
• | since the date of the Merger Agreement, there shall not have occurred any Material Adverse Effect that is continuing (the “MAE Condition”); and |
• | the Merger Agreement shall not have been terminated in accordance with its terms. |
Certain Legal Matters; Regulatory Approvals |
Fees and Expenses |
Miscellaneous |
Name, Position and Country of Citizenship | Present Principal Occupation or Employment; Material Positions Held During the Past Five Years | ||||
Charl van Zyl, President & Chief Executive Officer (United Kingdom) | Charl van Zyl joined Parent as its President & Chief Executive Officer in September 2023. He has more than 23 years of experience from commercial international management roles within the pharmaceutical industry. Prior to joining Parent, Mr. van Zyl served as Executive Vice President and Head of Neurology at UCB S.A. (Allée de la Recherche, 60, 1070 Brussels, Belgium), a biopharmaceutical company, from September 2019 to September 2023. Mr. van Zyl was responsible for UCB’s corporate activities in Europe and international markets. | ||||
Lars Søren Rasmussen,* Chairman of the Board (Denmark) | Lars Søren Rasmussen is the Chair of the Parent Board. He chairs the Remuneration & Nomination Committee and is a member of the Audit Committee. Mr. Rasmussen was first nominated for election to the Parent Board in 2013. Mr. Rasmussen was Chief Executive Officer of Coloplast A/S (Holtedam 1-3, DK-3050 Humlebaek, Denmark), a developer and manufacturer of medical devices, from 2008 to 2018. Mr. Rasmussen is Chair of the Board of Directors at Coloplast A/S and WS Audiology (Nymøllevej 6, 3540 Lynge, Denmark) a manufacturer of hearing aids. He also serves on the Board of Directors of Gyldendal A/S (Klareboderne 3, 1001 København K, Denmark), a publishing house. | ||||
Lene Skole-Sørensen,* Deputy Chair of the Board (Denmark) | Lene Skole-Sørensen is the Chief Executive Officer of the Lundbeck Foundation and Deputy Chair of the Parent Board. Prior to joining the Lundbeck Foundation in 2014, Lene was Chief Financial Officer at Coloplast A/S (Holtedam 1-3, DK-3050 Humlebaek, Denmark), a developer and manufacturer of medical devices. Lene Skole-Sørensen is Deputy Chair of the Parent Board, Ørsted A/S (Kraftværksvej 53, Skærbæk, 7000 Fredericia, Denmark), a sustainable energy company, Falck A/S (Sydhavnsgade 18, 2450 Copenhagen SV, Denmark), (Sydhavnsgade 18, 2450 København, Denmark), an emergency response and healthcare services provider. and ALK-Abelló A/S (Bøge Alle 1, 2970 Hørsholm, Denmark), a pharmaceutical company. She is the Vice Chair of Nordea Bank Abp (Satamaradankatu 5, FI-00020 Nordea, Finland). | ||||
Joerg Hornstein, CFO & Executive Vice President, Corporate Functions (Germany) | Joerg Hornstein joined Parent as its Chief Financial Officer in August 2022. Joerg served as Executive Vice President and Chief Financial Officer of AC Immune SA (EPFL Innovation Park, Building B, 1015 Lausanne, Switzerland), a Nasdaq-listed clinical-stage biopharmaceutical company, from April 2017 to July 2022, where he oversaw various corporate functions. | ||||
Santiago Arroyo* (USA) | Dr. Santiago Arroyo, MD and PhD, was first nominated for election to the Parent Board in 2021 and is a member of the Scientific Committee. Dr. Arroyo has more than 30 years of experience in academic neurology and pharmaceutical research and development. As an academic neurologist, Dr. Arroyo held faculty positions at the Johns Hopkins Hospital, Hospital Clinic of Barcelona | ||||
Name, Position and Country of Citizenship | Present Principal Occupation or Employment; Material Positions Held During the Past Five Years | ||||
and the Medical College of Wisconsin where he was Associate Professor of Neurology. He has special expertise in pediatric and adult epilepsy and electrophysiology. Santiago Arroyo serves as a member of the Board of Directors at GlycoEra AG (Einsiedlerstrasse 34, 8820 Wädenswil, Switzerland), a development-stage biotechnology company. | |||||
Jeffrey Berkowitz* (USA) | Jeffrey Berkowitz was first nominated for election to the Parent Board in 2018 and is a member of the Scientific Committee and the Remuneration & Nomination Committee. Mr. Berkowitz has served as the Chief Executive Officer of Real Endpoints (25A Hanover Road, Suite 203, Florham Park, New Jersey 07932), a market-access platform and advisory firm, since 2018. Mr. Berkowitz is Chair of the Board of Pharma Two B Ltd. (Pekeris St., Welzmann Science Park, Rehovot, Israel, 70400), a late-clinical stage company. He is also a member of the Board of Directors of Zealand Pharma A/S (Sydmarken 11, 2860 Søborg, Denmark), a biotechnology research company, and Click Therapeutics (80 White Street, 3rd Floor, New York, New York 10013), a software developer. | ||||
Lars Erik Holmqvist* (Sweden) | Lars Holmqvist has been a member of the Lundbeck Foundation Board since 2016. He serves as a member of the Research and Prize Committee. Lars is Chairman of the Board of Directors of Biovica International AB (Dag Hammarskjölds Väg 54B, 752 37 Uppsala, Sweden), a biotech company. He is a member of the Board of Directors of each of ALK-Abelló A/S (Bøge Alle 1, 2970 Hørsholm, Denmark), a pharmaceutical company, Tecan AG (Sveavägen 159, 1tr, 113 46 Stockholm, Sweden), a supplier of laboratory automation products, Vitrolife AB, a provider of medical devices and genetic testing services, and Naga UK Topco Ltd., a holding company (Dagger Lane Elstree, WD6 3BX, United Kingdom). Dr. Holmqvist is a professor, Chief Physician, and Head of Institute of Spots Medicine, Department of Orthopedic Surgety at Bispebjerg Hospital. He is also a Coordinating Professor for Bispebjerg-Frederiksberg Hospital, Institute of Clinical Medicine, University of Copenhagen. | ||||
Jakob Riis* (Denmark) | Jakob Riis was first nominated for election to the Parent Board in 2023 and is a member of the Scientific Committee. Since 2017, Jakob Riis has served as the President and Chief Executive Officer of Falck A/S (Sydhavnsgade 18, 2450 København, Denmark), an emergency response and healthcare services provider. Mr. Riis currently serves as Chair of the Board of Directors in Falck Healthcare A/S and Response A/S, and a member of the Board of Directors of Falck Danmark A/S, each a subsidiary of Falck A/S. He is also a member of the Board of Directors of the Danish Chamber of Commerce. | ||||
Dorothea Wenzel* (Germany) | Dorothea Wenzel serves as Chair of the Audit Committee of the Parent Board. She had a long career at Merck KGaA (Frankfurter Strasse 250, Darmstadt, 64293, Germany) a science and technology company, where until August 2021 she served as Executive Vice President and Head of the Global Business Unit Surface Solutions. In | ||||
Name, Position and Country of Citizenship | Present Principal Occupation or Employment; Material Positions Held During the Past Five Years | ||||
2018 she was the Chief Financial Officer & Head of Strategy of the Performance Materials Division. Dorothea is also a member of the Board of Directors of Dentsply Sirona Inc. (13320-B, Ballantyne Corporate Pl., Charlotte, NC 28277), a dental equipment manufacturer, a member of the Supervisory Board of Servier Pharmaceuticals (200 Pier 4 Blvd., Boston, MA 02210), a pharmaceutical manufacturer, and a member of the supervisory board of Gerresheimer AG (Klaus Bungert Str. 4 40468 Düsseldorf Germany), a pharmaceutical manufacturer. | |||||
Camilla Gram Andersson* (Denmark) | Camilla Gram Andersson has worked at Parent since 2005 and is an employee representative on the Parent Board. She is a Senior Director in the Corporate Health, Safety & Environment (HSE) department, where she is responsible for the development of Lundbeck’s HSE strategy. | ||||
Hossein Armandi,* (Denmark) | Hossein Armandi has worked at Parent since 1995 and is an employee representative on the Parent Board. He holds a position as Research Technician in the research department of Translational Drug Metabolism and Pharmacokinetics. | ||||
Dorte Clausen* (Denmark) | Dorte Clausen has worked at Parent since 2012 and is an employee representative on the Parent Board. She currently manages clinical studies within psychiatry and holds a position as Clinical Trial Manager, Specialist. Dorte is a member of the Board of a Danish union, Pharmadanmark (Gl. Kongevej 60, 1850 Frederiksberg C, Denmark), as well as a member of the Board at Training & Conference Center Pharmakon (Milnersvej 42, Hillerød, Region of the Capital DK-3400, Denmark), one of the largest dedicated conference centers in Denmark. | ||||
Lasse Skibsbye* (Denmark) | Lasse Skibsbye has worked at Parent since 2016 and is an employee representative on the Parent Board. He currently holds a position as Principal Scientist and Safety Pharmacologist in the department of Exploratory Toxicology, Non-clinical Safety Research. | ||||
Dianne Hol, Executive Vice President, People & Culture (The Netherlands) | Dianne Hol joined Parent as the Executive Vice President People & Culture in April 2024. Dianne served as Vice President Global Human Resources from March 2017 to April 2024 at AstraZeneca PLC (1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom), a biopharmaceutical business. | ||||
Johan Luthman, Executive Vice President, Research & Development (Sweden) | Johan Luthman joined Parent as Executive Vice President, R&D in March 2019. Johan holds a PhD in Neurobiology and Histology from the Karolinska Institute in Sweden. | ||||
Lars Bang, Executive Vice President, Product Development & Supply (Denmark) | Lars Bang was appointed as Senior Vice President, Supply Operations & Engineering in 2003. He began his career at Lundbeck in 1988 as a trainee in R&D. Subsequently, he has head R&D Planning, Corporate Planning and Strategy, Lundbeck España S.A, Group Sales & Marketing. In 2003 he was appointed Group Senior Vice President Supply Operations & Engineering. Lars is a Member of the Board of Claudio Bidco A/S (Dandyvej 19. Vejle, 7100,. Denmark), a pharmaceuticals manufacturer, Claudio Holdco A/S (Dandyvej 19. Vejle, 7100,. Denmark), a pharmaceuticals manufacturer, Fertin Pharma A/S (Dandyvej 19. Vejle, 7100,. Denmark), a pharmaceuticlsmanufacturer and OB Holdings (SW 22 54 2 W 4 MARWAYNE, AB, T0B 2X0 Canada), a food and beverage manufacturer. | ||||
Name, Position and Country of Citizenship | Present Principal Occupation or Employment; Material Positions Held During the Past Five Years | ||||
Maria Alfaiate, Executive Vice President, Commercial & Corporate Strategy (Portugal) | Maria Alfaiate joined Parent as Executive Vice President Commercial and Corporate Strategy, August 1, 2024. Maria previously held positions at Bayer Pharmaceuticals(51368 Leverkusen, Germany), a pharmaceutical company, where she served as Senior Vice President and Global Head of New Products Commercialization and Portfolio Strategy from August 2021 to August 2024, Global VP Cardio, Renal & Vascular Diseases from September 2020 to August 2021 and Global Cardio-Renal Head from April 2020 to September 2020. Prior to her time at Bayer, Maria was a Global Brand Director from January 2018 to April 2020 at AstraZeneca PLC (1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom), a biopharmaceutical business. | ||||
Michala Fischer-Hansen, Executive Vice President, Head of Europe & International Markets (Denmark) | Michala Fischer-Hansen joined Parent as the Executive Vice President Head of Europe & International Markets in April 2024. From 2019 to March 2024 she was an Executive Vice President at Falck A/S (Sydhavnsgade 18, 2450 København, Denmark), an emergency response and healthcare services provider. | ||||
Thomas Gibbs, Executive Vice President, Head of Lundbeck U.S. (USA) | Mr. Gibbs has served as Executive Vice President, Head of Lundbeck U.S., and President of Payor since February 2023. Prior to joining, Thomas Gibbs served as Chief Executive Officer and Global Brand Leader for Vectura, Inc. (Chippenham, 1-6, Prospect West, Bumpers Way, United Kingdom), a pharmaceutical company, from December 2021 to February 2023. Mr. Gibbs served as Senior Vice President and Chief Commercial Officer for Sunovion Pharmaceuticals (84 Waterford Dr, Marlborough, MA 01752), a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions, from November 2019 to December 2021. Mr. Gibbs was Executive Vice President and Chief Commercial Officer for Optinose US, Inc. (777 Township Line Road, Suite 300, Yardley, Pennsylvania 19067), a specialty pharmaceutical company focused on creating and bringing to market innovative products for patients with diseases treated by ear, nose, and throat and allergy specialists, from October 2016 to November 2019. | ||||
Tine Østergaard Hansen, Senior Vice President, Corporate Communications and Public Affairs (Denmark) | Tine Østergaard Hansen joined Parent as the Senior Vice President of Corporate Communications & Public Affairs in March 2024. Prior to joining Parent, she was the Vice President of Corporate Communications, Branding & Sustainability at Noble Corporation (13135 Dairy Ashford, Suite 800, Sugar Land, Texas, 77478), an offshore drilling company, from October 2022 to March 2024. She was Head of Corporate Communication and Branding at Maersk Drilling (Lyngby Hovedgade 85, Kongens Lyngby, 2800, DK), an offshore drilling company from July 2017 to May 2020 and Vice President, Head of Corporate Communication and Sustainability from May 2020 to October 2022. | ||||
Name and Country of Citizenship | Present Principal Occupation or Employment; Material Positions Held During the Past Five Years | ||||
Thomas Gibbs* President (USA) | Mr. Gibbs is the President of Purchaser. He has served as Executive Vice President, Head of Lundbeck U.S., and President of Payor since February 2023. Prior to joining, Thomas Gibbs served as Chief Executive Officer and Global Brand Leader for Vectura, Inc. (Chippenham, 1-6, Prospect West, Bumpers Way, United Kingdom), a pharmaceutical company, from December 2021 to February 2023. Mr. Gibbs served as Senior Vice President and Chief Commercial Officer for Sunovion Pharmaceuticals (84 Waterford Dr, Marlborough, MA 01752), a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions, from November 2019 to December 2021. Mr. Gibbs was Executive Vice President and Chief Commercial Officer for Optinose US, Inc. (777 Township Line Road, Suite 300, Yardley, Pennsylvania 19067), a specialty pharmaceutical company, from October 2016 to November 2019. | ||||
Markus Kede (Sweden) | Markus Kede is the Treasurer of Purchaser. He has served as Vice President, Finance & Business Planning, at Payor since August 2022. Prior to such position, Mr. Kede served as Senior Director, Treasury, at Parent from October 2014 through July 2022. | ||||
Thomas Forrester (USA and Ireland) | Thomas Forrester is the Secretary of Purchaser. He has served in various capacities at Payor and its predecessor, Lundbeck Inc., since April 2011. From 2017 to April 2020, he served as Vice President Legal Affairs & General Counsel, NA. Mr. Forrester’s responsibilities included Lundbeck’s legal operations in Canada from 2017-2022. He has served as Senior Vice President Legal Affairs & General Counsel, NA, since 2020. | ||||
2 | Parent controls Purchaser and Payor though its wholly owned subsidiary, Lundbeck USA Holding LLC, a Delaware limited liability company with its principal executive office located at 6 Parkway North, Deerfield, IL 60015. The telephone number of Lundbeck USA Holding LLC is (866) 377-6996. |
Name, Position and Country of Citizenship | Present Principal Occupation or Employment; Material Positions Held During the Past Five Years | ||||
Uma Sankar Dittakav, Chief Analytics Officer (USA) | Uma Sankar Dittakav joined Payor as Chief Analytics Officer in July 2023. Prior to joining Payor, Uma worked at Sunovion Pharmaceuticals (84 Waterford Dr, Marlborough, MA 01752), a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions, as the head of Decision Sciences for 12 years. | ||||
Michael Giordano, Assistant Treasurer (USA) | Michael Giordano has served as Senior Director, US Commercial Finance, and Assistant Treasurer of Payor since August 2022. From October 2021 to July 2022, Mr. Giordano was Director, US Commercial Finance. He was Assistant Controller from 2017 to 2020 and America Controller in 2021. | ||||
Puja Leekha, Chief Compliance Officer & Head of DEI Strategy (USA) | Puja Leekha has served as VP, Chief Compliance Officer & Head of DEI Strategy since November 2023. From August 2023 to November 2023, Puja served as SVP, Chief Ethics & Compliance Officer, Chief Legal Officer and Corporate Secretary at Orthofix Medical Inc. (3451 Plano Parkway, Lewisville, TX 75056), a medical device company. Puja served as VP, Chief Compliance Officer & Corporate Counsel at Payor from June 2018 to July 2023. | ||||
Thomas E. Gibbs,* Executive Vice President and Head of Lundbeck U.S. (USA) | Thomas E. Gibbs has served as Executive Vice President, Head of Lundbeck U.S., and President and Lead Manager of Payor since February 2023. Prior to joining, Thomas Gibbs served as Chief Executive Officer and Global Brand Leader for Vectura, Inc. (Chippenham, 1-6, Prospect West, Bumpers Way, United Kingdom), a pharmaceutical company, from December 2021 to February 2023. Mr. Gibbs served as Senior Vice President and Chief Commercial Officer for Sunovion Pharmaceutical (84 Waterford Dr, Marlborough, MA 01752)s, a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions, from November 2019 to December 2021. Mr. Gibbs was Executive Vice President and Chief Commercial Officer for Optinose US, Inc. (777 Township Line Road, Suite 300, Yardley, Pennsylvania 19067), a specialty pharmaceutical company focused on creating and bringing to market innovative products for patients with diseases treated by ear, nose, and throat and allergy specialists, from October 2016 to November 2019. | ||||
Molly Poarch, Vice President of Corporate Affairs and Commercial Operations (USA) | Molly Poarch has served as VP Corporate Affairs and Commercial Operations at Payor since July 2021. She has more than 20 years of progressive experience in communications and patient advocacy spanning across the pharmaceutical, biotech, medical device and nonprofit sectors. She holds a bachelor of science degree in organizational communications from Ohio University. Molly has also served as Vice President of Communications and Patient Advocacy for Orphazyme A/S (Lyskær 8A, DK-2730 Herlev, Copenhagen, Denmark), a therapeutics company, Senior Director of Portfolio Communications, Alexion Pharmaceuticals, Inc. (121 Seaport Blvd Boston, MA 02210,), a pharmaceutical company, and Senior Director of Corporate Communications for RTI Surgical (11621 Research Circle, Alachua, FL 32615), a surgical implant supplier. | ||||
Shae Maughmer, SVP Head of Commercial Neurology (USA) | Shae Maughmer has served as SVP Head of Commercial Neurology at Payor since July 2023. Shae was previously VP Business Unit Head Neurology at Payor from September 2020 to July 2023. Prior to joining Payor, Shae served as VP Franchise | ||||
Name, Position and Country of Citizenship | Present Principal Occupation or Employment; Material Positions Held During the Past Five Years | ||||
Head Biotherapeutics Specialty Care at Takeda Pharmaceuticals USA (500 Kendall Street, Cambridge, MA 02142), a biopharmaceutical company, from January 2019 to August 2020. | |||||
Joseph Bufalino, Vice President of Strategy and Portfolio Management (USA) | Joe Bufalino is currently the VP of Strategy and Portfolio Management in the US. Joe has been with Lundbeck since 2015, and during his 8.5 years at the company, he has held various roles across different functions. These roles include Business Development, Analytics, Market Research, Forecasting, Alliance Management, and New Product Planning. He has served as Vice President of Insights & Analytics, Senior Director of Business Insights, and Director of Commercial Assessment. Joe holds a BA in Economics from the University of Chicago and an MBA from the Kellogg School of Management at Northwestern. With almost 20 years of healthcare experience across the value chain, including Pharma, Payer, Providers, and PBMs, Joe brings a wealth of knowledge to his current role. Before joining Lundbeck, Joe worked for Strategy& (101 Park Avenue, 18th Floor, New York, NY 10178),the global strategy consulting team at PwC,, where he worked with numerous Fortune 500 and transformative clients in the healthcare space. | ||||
Markus Kede,* VP, Finance & Business Planning (Sweden) | Markus Kede has served as Vice President, Finance & Business Planning, and as Treasurer and a Manager of Payor since August 2022. Prior to such positions, Mr. Kede served as Senior Director, Treasury, at Parent from October 2014 through July 2022. | ||||
Marija Simin Geertsen, VP US Medical Affairs (Croatia & Denmark) | Marija Simin Geertsen has served as VP US Medical Affairs for Payor since January 2021. She previously served as Senior Director, Medical and Regulatory Affairs at Lundbeck Canada Inc., a subsidiary of Parent, from March 2019 to January 2021. | ||||
Thomas D. Forrester, Secretary; SVP Legal and Government Affairs & General Counsel, NA; (USA and Ireland) | Thomas Forrester has served in various capacities at Payor and its predecessor, Lundbeck Inc., since April 2011. From 2017 to April 2020, he served as Vice President Legal Affairs & General Counsel, NA. Mr. Forrester’s responsibilities included Lundbeck’s legal operations in Canada from 2017-2022. He has served as Senior Vice President Legal Affairs & General Counsel, NA, since 2020. | ||||
Brad Dempsey Vice President Human Resources (USA) | Mr. Dempsey has served as Vice President, Human Resources, at Payor since May 2022. Prior to assuming such position, Mr. Dempsey was Senior Director, Human Resources, at Payor from November 2020 to May 2022. Prior to joining Payor, Mr. Dempsey served as Director of Business Human Resources at AbbVie Inc. (1 N. Waukegan Road, North Chicago, Illinois 60064), a biopharmaceutical company, from October 2016 to November 2020. | ||||
John M. Spinnato* (USA) | John Spinnato is a lawyer in the health care industry, most recently practicing in New York City for Pfizer Inc. (66 Hudson Boulevard East, New York, New York 10001), a multinational pharmaceutical and biotechnology corporation, as a contractor through Axion Legal from April 2020 to September 2024. Prior to such role, Mr. Spinnato served as the Chief Executive Officer of DKMS US (40 Fulton Street, 26th Floor, New York, NY 10038), a not-for-profit focused on finding stem cell and bone marrow donors for patients with blood cancers and disorders, from September 2019 to early 2020. John has been a Manager of Payor since June 2019. | ||||
Name, Position and Country of Citizenship | Present Principal Occupation or Employment; Material Positions Held During the Past Five Years | ||||
Lene Skole-Sørensen, Chief Executive Officer (Denmark) | Lene Skole-Sørensen is the Chief Executive Officer of the Lundbeck Foundation and Deputy Chair of the Parent Board. Prior to joining the Lundbeck Foundation in 2014, Lene was Chief Financial Officer at Coloplast A/S (Holtedam 1-3, DK-3050 Humlebaek, Denmark), a developer and manufacturer of medical devices. Lene Skole-Sørensen is Deputy Chair of the Parent Board, Ørsted A/S (Kraftværksvej 53, Skærbæk, 7000 Fredericia, Denmark), a sustainable energy company, Falck A/S (Sydhavnsgade 18, 2450 Copenhagen SV, Denmark), (Sydhavnsgade 18, 2450 København, Denmark), an emergency response and healthcare services provider. and ALK-Abelló A/S (Bøge Alle 1, 2970 Hørsholm, Denmark), a pharmaceutical company. She is the Vice Chair of Nordea Bank Abp (Satamaradankatu 5, FI-00020 Nordea, Finland). | ||||
Steffen Kragh,* Chair (Denmark) | Steffen Kragh is Chair of the Board of the Lundbeck Foundation. He has served as the President & CEO of Egmont International Holding A/S (Vognmagergade 11, 1148 København K, Denmark), a media corporation, as well as its philanthropic arm, the Egmont Foundation, since 2001. Mr. Kragh is Deputy Chair of Tryg A/S (Klausdalsbrovej 601, 2750 Ballerup, Denmark), a Scandinavian insurance company, and Tryg Forsikring A/S, its affiliate. | ||||
Søren Skou,* Deputy Chair (Denmark) | Søren Skou was elected to the Lundbeck Foundation Board in 2024 and is the Deputy Chair and a member of the Investment Committee. Mr. Skou was Chief Executive Officer of A.P. Moller-Maersk A/S (Esplanaden 50 1263 Copenhagen K, Denmark), a shipping and logistics company, from 2016 to December 2022. Mr. Skou is the Chair of the Advisory Committee of VTG GmbH (Nagelsweg 34, 20097 Hamburg, Germany), and Skyborn Renewables GmBH (Ericusspitze 2-4, 20457 Hamburg, Germany), portfolio companies of Global Infrastructure Partners, an infrastructure fund. He is also the Chair of (i) Controlant hf. (Smáratorg 3,201 Kópavogur, Iceland), a supply chain company, (ii) Bygma A/S (Transformervej 10, 2860 Søborg, Denmark), a building materials company, and (iii) C.W. Obel (Vestergade 2, DK-1456 København K, Denmark), an investment company. He is also the independent chair of the Supervisory Board of HES International BV (‘De Rotterdam’, 28th Floor, Wilhelminakade 143, 3072 AP Rotterdam, The Netherlands), a bulk handling company. | ||||
3 | The Lundbeck Foundation controls the Parent though its wholly owned subsidiary, Lundbeckfond Invest A/S. The principal executive office of Lundbeckfond Invest A/S is located at Scherfigsvej 7, DK-2100 Copenhagen, Denmark. The telephone number of Lundbeckfond Invest A/S is +45 39 12 80 00. |
Name, Position and Country of Citizenship | Present Principal Occupation or Employment; Material Positions Held During the Past Five Years | ||||
Lars Holmqvist* (Sweden) | Lars Holmqvist was first elected to the Lundbeck Foundation Board in 2015 and is the Chair of the Investment Committee. Mr. Holmqvist is Chairman of the Board of Directors of Biovica International AB (Dag Hammarskjölds Väg 54B, 752 37 Uppsala, Sweden), a biotech company. He is a member of the Board of Directors of each of ALK-Abelló A/S (Bøge Alle 1, 2970 Hørsholm, Denmark), a pharmaceutical company, Tecan AG (Sveavägen 159, 1tr, 113 46 Stockholm, Sweden), a supplier of laboratory automation products, Vitrolife AB, a provider of medical devices and genetic testing services, and Naga UK Topco Ltd., a holding company (Dagger Lane Elstree, WD6 3BX, United Kingdom). | ||||
Michael Kjær* (Denmark) | Michael Kjær was first elected to the Lundbeck Foundation Board in 2016 and is a member of the Research and Prize Committee. Dr. Kjær is the head of the Institute of Sports Medicine, Department of Orthopedic Surgery, at Bispebjerg Hospital. He is has been a coordinating Professor for Bispebjerg-Frederiksberg Hospital, Institute of Clinical Medicine, University of Copenhagen since 1997. | ||||
Susanne Krüger Kjær* (Denmark) | Susanne Krüger Kjær was first elected to the Lundbeck Foundation Board in 2014 and is a member of the Research and Prize Committee. Since 2005, she has been a clinical professor in Cancer Epidemiology at the Department of Gynecology, Rigshospitalet, University of Copenhagen. | ||||
Svend Andersen* (Denmark) | Svend Anderson is a member of the Investment Committee of the Lundbeck Foundation Board of Directors. From February 2017 through July 2024, Mr. Andersen served as Executive Vice President and President, Consumer Self-Care International, for Perrigo Company plc (The Sharp Building, Hogan Place, Dublin 2, Ireland, D02 TY74), an NYSE-listed provider of self-care products and health and wellness solutions. | ||||
Henrik Sindal Jensen* (Denmark) | Henrik Sindal Jensen has been a member of the Lundbeck Foundation Board since 2022. He is Senior Director, Corporate Business Development and Strategy at Parent. | ||||
Katja Barnkob* (Denmark) | Katja Barnkob was first elected to the Lundbeck Foundation Board in 2022. She is the Senior Project Director, Global Clinical Development, at ALK-Abelló A/S (Bøge Alle 1, 2970 Hørsholm, Denmark), a pharmaceutical company, as well as a Board member. | ||||
Mikkel Helmer Nielsen* (Denmark) | Mikkel Helmer Nielsen has been a member of the Lundbeck Foundation Board since 2022. He has served in many roles, including Head of Technology, Digital Progam Manager, Project Manager, and Emergency Manager. He is also a member of the board of Falck Danmark (Sydhavnsgade 18, 2450 København, Denmark), an emergency response and healthcare services provider. | ||||
Morten Aagaard* (Denmark) | Morten Aagaard has been a member of the Lundbeck Foundation Board since 2022. He is a member of the board of Falck Danmark (Sydhavnsgade 18, 2450 København, Denmark), an emergency response and healthcare services provider. He also serves as a trained paramedic for Falck. | ||||
Thomas Mears Werge* (Denmark) | Thomas Mears Werge has been a member of the Lundbeck Foundation Board since 2023, and he also serves as a member of the Research and Prize Committee. Thomas is a professor as well as Director of Institutional Biology, Psyciatry,and Mental Health Services at Copenhagen University Hospital. He also serves as a board member of the National Genome Centre, as well as a member of the Strategic Research Council at Copenhagen University Hospital. He is a Principal Investigator for NIH & EU Initiatives on Mental Disorders. He is an Expert Witness for (WADA) CAS, Court of Arbitration for Sport, Lausanne (Schweiz). Thomas also serves as a board member of Sputnik Holding JAC ApS (Hejrevej 43, 2400 København NV), a | ||||
Name, Position and Country of Citizenship | Present Principal Occupation or Employment; Material Positions Held During the Past Five Years | ||||
financial holding company, Sputnikkollegiet Frederiksberg ApS (Kong Georgs Vej 65, 2000 Frederiksberg, Denmark), a financial holding company, Sputnikkollegiet Virum ApS, and Sputnikkollegiet Virum ApS (Skovridergårdsvej 23, 2830 Virum, Denmark), a financial holding company. | |||||
Jan Egebjerg Senior Vice President, Grants & Prizes, Director of Science (Denmark) | Jan Egebjerg joined the Lundbeck Foundation in August 2019 and is responsible for the Lundbeck Foundation’s philanthropic grants and prizes. He has worked in the fields of Central Nervous System research and research management since 1990. | ||||
Christian Elling, Senior Vice President, Managing Partner, Lundbeckfonden BioCapital (Denmark) | Mr. Elling joined the Lundbeck Foundation in 2012 and heads Lundbeckfonden BioCapital, the early-stage biotech investment unit for the Lundbeck Foundation. Mr. Elling is the Chair of SNIPR Biome ApS (Lersø Parkallé 44, 2100 Copenhagen, Denmark), a microbial gene therapy company, and SNIPR Holdings ApS, a related entity. He is also the Chair of Cytoki Pharma, ApS (Vandtårnsvej 77, DK-2860 Søborg, Denmark), a clinical-stage biotechnology company, Mr. Elling is a board member of IO Biotech, Inc. (Ole Maaløes Vej 3, DK-2200 Copenhagen N, Denmark), a Nasdaq-listed biopharmaceutical company, and NMD Pharma (Palle Juul-Jensens Boulevard 82 8200 Aarhus N, Denmark), also a biopharmaceutical company. | ||||
Søren Christiansen, Senior Vice President, Finance & HR (Denmark) | Søren Christiansen has served as head of Finance for the Lundbeck Foundation since August 2017 and is responsible for IT, tax and accounts. | ||||
Peter Rothausen, Senior Vice President, Financial Investments and Head of Invest (Denmark) | Peter Rothausen has served as investment manager for the Lundbeck Foundation since May 2018. | ||||
Arne Due-Hansen, Senior Vice President, Strategic Ownership (Denmark) | Arne Due-Hansen has been employed as Senior Vice President, Strategic Ownership at the Lundbeck Foundation since September 2022 and is responsible for strategic investments. From 2014 to 2022, Mr. Due-Hansen was Senior Strategic Advisor at Danske Bank (Bernstorffsgade 40, 1577 København, Denmark), a Danish bank. Mr. Due-Hansen is a board member of WSA A/S (Nymøllevej 6, 3540 Lynge, Denmark), a hearing aid producer, Ellab A/S (Trollesmindealle 25, 3400 Hilleroed, Denmark), a provider of validation and monitoring solutions for biotech and pharmaceutical companies, and Ferrosan Medical Devices A/S (Sydmarken 5, DK-2860 Søborg, Denmark), a developer and producer of medical products. | ||||
The Depositary for the Offer is: | |||
Broadridge Corporate Issuer Solutions, LLC | |||
If delivering by mail: | If delivering by express mail, courier, or other expedited service | ||
Broadridge Corporate Issuer Solutions, LLC Attention: BCIS Re-Organization Department P.O. Box 1342 Brentwood, NY 11717-0718 | Broadridge Corporate Issuer Solutions, LLC Attention: BCIS IWS 51 Mercedes Way Edgewood, NY 11717 | ||
